undamentalytics Newsletter
Sign in

Can-fite Biopharma Ltd. revenue

Can-fite Biopharma Ltd.'s revenue was $405,000 in fiscal 2025, down 39.9% on the year before. Since fiscal 2018 ($3.8m) it has grown at a compound -27.4% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue3,8202,032763853810743674405
Growth on the year before—−46.8%−62.5%+11.8%−5.0%−8.3%−9.3%−39.9%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Can-fite Biopharma Ltd. $405,000 -39.9% —
Cervomed Inc. $331,295 -95.7% -52.7%
Cardiff Oncology, Inc. $508,000 -7.0% 7.2%
Clene Inc. $197,000 -31.1% -36.9%
Medicinova Inc $920,481 875.7% —
Shattuck Labs, Inc. $1.0m -66.6% 5.2%

Compare with peers

Head to head: CANF vs CRVOCANF vs CRDFCANF vs CLNN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Can-fite Biopharma Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Can-fite Biopharma Ltd.